Nuclear Medicine and Biology
Volume 37, Issue 1 , Pages 3-8 , January 2010

In vivo [11C]dihydrotetrabenazine binding in rat striatum: sensitivity to dopamine concentrations

  • Michael R. Kilbourn

      Affiliations

    • Department of Radiology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    • Corresponding Author InformationCorresponding author. Cyclotron/Radiochemistry Facility, University of Michigan, Ann Arbor, MI 48109, USA. Tel.: +1 734 763 9246; fax: +1 734 615 2557.
    • ,
  • Elizabeth R. Butch

      Affiliations

    • Department of Radiology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    • ,
  • Timothy Desmond

      Affiliations

    • Department of Radiology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    • ,
  • Phillip Sherman

      Affiliations

    • Department of Radiology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    • ,
  • Paul E. Harris

      Affiliations

    • Department of Medicine, Columbia University Medical College, New York, NY 10032, USA
    • ,
  • Kirk A. Frey

      Affiliations

    • Department of Radiology, University of Michigan Medical School, Ann Arbor, MI 48109, USA

Received 23 July 2009 ,Revised 28 August 2009 ,Accepted 31 August 2009.

References 

  1. Frey KA, Koeppe RA, Kilbourn MR. Imaging the vesicular monoamine transporter. In: Advances in neurology. Philadelphia: Lippincott, Williams and Wilkins; 2001;p. 237–247
  2. Albin RL, Koeppe RA, Bohnen NI, Nichols TE, Meyer P, Wernette K, et al. Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology. 2003;61:310–315
  3. Bohnen NI, Koeppe RA, Meyer P, Ficaro E, Wernette K, Kilbourn MR, et al. Decreased striatal monoaminergic terminals in Huntington disease. Neurology. 2006;54:1753–1759
  4. Bohnen NI, Albin RL, Koeppe RA, Wernette KA, Kilbourn MR, Minoshima S, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab. 2006;26:1198–1212
  5. De La Fuente-Fernandez R, Furtado S, Guttman M, Furukawa Y, Lee CS, Calne DB, et al. VMAT2 binding is elevated in DOPA-responsive dystonia: visualizing empty vesicles by PET. Synapse. 2003;49:20–28
  6. Gilman S, Koeppe RA, Chervin RD, Consens FB, Little R, An H, et al. REM sleep behavior disorder is related to striatal monoaminergic deficit in MSA. Neurology. 2003;61:29–33
  7. Koeppe RA, Gilman S, Joshi A, Liu S, Little R, Junck L, et al. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. J Nucl Med. 2005;46:936–944
  8. Martin WRW, Wieler M, Stoessl J, Schulzer M. Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Ann Neurol. 2008;63:388–394
  9. Zubieta JK, Taylor SF, Huguelet P, Koeppe RA, Kilbourn MR, Frey KA. Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects. Biol Psychiatry. 2001;49:110–116
  10. Kilbourn MR, Frey KA, Vander Borght T, Sherman PS. Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters. Nucl Med Biol. 1996;23:467–471
  11. Naudon L, Leroux-Nicollet I, Costentin J. Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter. Neurosci Lett. 1994;173:1–4
  12. Vander Borght TM, Kilbourn MR, Desmond TJ, Kuhl DE, Frey KA. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol. 1995;294:577–583
  13. Vilpoux C, Leroux-Nicollet I, Naudon L, Raisman-Vozari R, Costentin J. Reserpine or chronic fluoxetine treatments do not modify the vesicular monoamine transporter 2 expression in serotonin-containing regions of the rat brain. Neuropharm. 2000;39:1075–1082
  14. Wilson JM, Kish SJ. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci. 1996;16:3507–3510
  15. Tong J, Wilson AA, Boileau I, Houle S, Kish SJ. Dopamine modulating drugs influence striatal (+)-[11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. Synapse. 2008;62:873–876
  16. De La Fuentes-Fernandez R, Sossi V, McCormick S, Shulzer M, Ruth TJ, Stoessl AJ. Visualizing vesicular dopamine dynamics in Parkinson's disease. Synapse. 2009;63:713–716
  17. Kilbourn MR, Butch ER, Desmond T, Sherman P, Frey KA. Dopamine depletion increases in vivo [11C]DTBZ binding in awake rat brain. NeuroImage. 2008;41(Suppl. 2):T54
  18. Jewett DM, Kilbourn MR, Lee LC. A simple synthesis of [11C]dihydrotetrabenazine. Appl Radiat Isot. 1997;24:197–199
  19. Kilbourn M, Sherman P. In vivo binding of (+)-α-[3H]dihydrotetrabenazine to the vesicular monoamine transporter of rat brain: bolus vs. equilibrium studies. Eur J Pharmacol. 1997;331:161–168
  20. Kilbourn MR. Long-term reproducibility of in vivo measures of specific binding of radioligands in rat brain. Nucl Med Biol. 2004;31:591–595
  21. Frey K, Kilbourn M, Robinson T. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur J Pharmacol. 1997;334:273–279
  22. Widerlov E, Lewander T. Inhibition of the in vivo biosynthesis and changes of catecholamine levels in rat brain after α-methyl-p-tyrosine: time and dose–response relationships. Naunyn Schmiedebergs Arch Pharmacol. 1978;304:111–123
  23. Naudon L, Leroux-Nicollet I, Raisman-Vozari R, Botton D, Costentin J. Time-course of modifications elicited by reserpine on the density and mRNA synthesis of the vesicular monoamine transporter, and on the density of the membrane dopamine uptake complex. Synapse. 1995;21:29–36
  24. Gatley SJ, Volkow ND, Fowler JS, Dewey SL, Logan J. Sensitivity of striatal [11C]cocaine binding to decreases in synaptic dopamine. Synapse. 1995;20:137–144
  25. Gatley SJ, Ding YS, Volkow ND, Chen R, Sugano Y, Fowler JS. Binding of d-threo-[11C]methylphenidate to the dopamine transporter in vivo: insensitivity to synaptic dopamine. Eur J Pharmacol. 1995;281:141–149
  26. Ikawa K, Watanabe A, Kaneno S, Toru M. Modulation of [3H]mazindol binding sites in rat striatum by dopaminergic agents. Eur J Pharmacol. 1993;250:261–266
  27. Scheffel U, Steinart C, Kim SE, Ehlers MD, Boja JW, Kuhar MJ. Effect of dopaminergic drugs on the in vivo binding of [3H]WIN 35,428 to the central dopamine transporters. Synapse. 1996;23:61–69
  28. Buu NT. Vesicular accumulation of dopamine following l-DOPA administration. Biochem Pharmacol. 1989;38:1787–1792
  29. Doshi PS, Edwards DJ. Effects of l-DOPA on dopamine and norepinephrine concentrations in rat brain assessed by gas chromatography. J Chromatogr. 1981;210:505–551
  30. Wachtel SR, Abercrombie ED. l-3,4-Dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem. 1994;63:108–117
  31. Zahniser NR, Doolen S. Chronic and acute regulation of Na/Cl−-dependent neurotransmitter transporters: drugs, substrates, presynaptic receptors and signaling systems. Pharmacol Ther. 2001;92:21–55

PII: S0969-8051(09)00222-4

doi: 10.1016/j.nucmedbio.2009.08.013

Nuclear Medicine and Biology
Volume 37, Issue 1 , Pages 3-8 , January 2010

Article Tools

* Image Usage & Resolution